SEARCH

SEARCH BY CITATION

References

  • 1
    Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2012. Lancet. 2013;380:22242260.
  • 2
    Landsberg L, Aronne LJ, Beilin L, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:1433.
  • 3
    Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; Nov 12 [Epub ahead of print].
  • 4
    Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; Nov 7 [Epub ahead of print].
  • 5
    Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013; Nov 7 [Epub ahead of print].
  • 6
    Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; Nov 7 [Epub ahead of print].
  • 7
    Brook RD, Appel LJ, Rubenfire M, et al. American Heart Association Professional Education Committee of the Council for High Blood Pressure Research; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Nutrition, Physical Activity. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 2013;61:13601383.
  • 8
    Levine GN, Allen K, Braun LT, et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing. Pet ownership and cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2013;127:23532363.
  • 9
    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2013;16:1446.
  • 10
    James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507520.
  • 11
    Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:12811357.
  • 12
    Schmieder RE, Redon J, Grassi G, et al. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention. 2013;9(Suppl R):R58R66.
  • 13
    O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:17311768.
  • 14
    Mahfoud F, Lüscher TF, Andersson B, et al. European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:21492157.
  • 15
    Cooke CR, Gould MK. Advancing clinical practice and policy through guidelines: the role of the American Thoracic Society. Am J Respir Crit Care Med. 2013;187:910914.
  • 16
    National Academies. Guidelines for the review of National Academies reports. Available at: http://www.nationalacademies.org/xpedio/groups/nasite/documents/webpage/na_067076.pdf. Accessed January 14, 2014.
  • 17
    Sox HC. Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA. 2014;311:472474.
  • 18
    Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 19
    Gibbons GH, Shurin SB, Mensah GA, Lauer MS. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2013;62:13961398.
  • 20
    Gibbons GH, Harold JG, Jessup M, et al. The next steps in developing clinical practice guidelines for prevention. J Am Coll Cardiol. 2013;62:13991400.
  • 21
    Wright JT Jr, Fine LJ, Lackland DT, et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; Jan 14 [Epub ahead of print].
  • 22
    Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes? JAMA. 2014;311:474476.
  • 23
    Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014;311:477478.
  • 24
    Gulati V, White WB. Review of the state of renal nerve ablation for patients with severe and resistant hypertension. J Am Soc Hypertens. 2013;7:484493.
  • 25
    The Editors. Hypertension Editors’ Picks: renal denervation. Hypertension. 2013;62:e26e30.
  • 26
    Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart 2013;99:15791587.
  • 27
    Turner JR, O'Brien E. Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15:868873.
  • 28
    Persu A, Renkin J, Asayama K, et al. Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739749.
  • 29
    Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150156.
  • 30
    Howard JP, Cole GD, Sievert H, et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014; Jan 8 [Epub ahead of print].
  • 31
    Esler MD, Krum H, Sobotka PA, et al. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:19031909.
  • 32
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:12751281.
  • 33
    Symplicity HRN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911917.
  • 34
    Krum H, Schlaich MP, Böhm M, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2013; Nov 6 [Epub ahead of print].
  • 35
    Esler MD, Krum H, Schlaich M, et al. Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:29762982.
  • 36
  • 37
    Weber MA. Exploring issues in difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2013;15:859864.
  • 38
    Turner JR. Patient and physician adherence in hypertension management. J Clin Hypertens (Greenwich). 2013;15:447452.
  • 39
    Whitford DL, Al-Anjawi HA, Al-Baharna MM. Impact of clinical inertia on cardiovascular risk factors in patients with diabetes. Prim Care Diabetes. 2013; Nov 22 [Epub ahead of print].
  • 40
    Escobar C, Barrios V, Alonso-Moreno FJ, et al. Working Group of Arterial Hypertension of the Spanish Society of Primary Care Physicians (Group HTA/SEMERGEN); PRESCAP 2010 investigators. New blood pressure control goals, more rational but facilitating therapeutic inertia? J Hypertens. 2013;31:2462.
  • 41
    Márquez-Contreras E, Gil-Guillén VF, De La Figuera-Von Wichmann M, et al. Working Group on Non-compliance and Inertia, Spanish Society of Hypertension (SHE-LELHA). Non-compliance and inertia in hypertensive Spaniards at high cardiovascular risk: CUMPLE study. Curr Med Res Opin. 2014;30:1117.
  • 42
    Desai N, Madhavankutty Saraswathy V, Hunter K, McFadden C. Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic. J Clin Hypertens (Greenwich). 2013;15:375379.
  • 43
    Germino FW. Therapeutic inertia and measurement inertia in hypertension: a call to action. J Clin Hypertens (Greenwich). 2013;15:365366.
  • 44
    Fontil V, Pletcher MJ, Khanna R, et al. Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010. J Gen Intern Med. 2013; Nov 19 [Epub ahead of print].
  • 45
    Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218225.
  • 46
    Michie S, Johnston M. Changing clinical behaviour by making guidelines specific. BMJ. 2004;328:343345.
  • 47
    Rümenapf G. Incomprehensible jargon. Dtsch Arztebl Int. 2011;108:492.